Home › Premature Birth › NCT05380401
Metabolic Mechanisms Induced by Enteral DHA and ARA Supplementation in Preterm Infants
Recruiting
Metabolic Mechanisms Induced by Enteral Docosahexaenoic Acid (DHA) and Arachidonic Acid (ARA) Supplementation in Preterm Infants
Who can join
36 Weeks · All sexes
Full eligibility criteria
Inclusion Criteria: * born between 25 0/7 and 29 6/7 weeks of gestation * less than 48 hours of age at first lipid dose (The cohort is defined by gestational age rather than birth weight to avoid an over-represented sample of growth-restricted infants in birth weight defined cohorts.) Exclusion Criteria: * serious congenital anomalies * conditions at birth that will require surgery prior to discharge * imminent death such that withdrawal of intensive care support is anticipated within the first 72 hours after birth
About the study
A comprehensive analysis of the impact of exogenous enteral DHA and ARA supplementation on lipid metabolism including the production of downstream derived mediators and how this impacts important biological pathways such as metabolism, inflammation, and organogenic factors.
What is being tested
- Enfamil® DHA & ARA Supplement for Special Dietary Use (dietary supplement)
Sponsor: The University of Texas Health Science Center at San Antonio · Participants: 328 · Started: Mar 9, 2023
Contact the study team
- Cynthia Blanco, MD, MSCI-TS · Phone: 210-567-5225
- Diana Anzueto Guerra · Phone: 210-567-5254
Official record on ClinicalTrials.gov — NCT05380401
Locations in the U.S.
Conditions
From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.